De-indexed estimated glomerular filtration rates for the dosing of oral antidiabetic drugs in patients with chronic kidney disease
Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m 2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of p...
Saved in:
| Published in: | Frontiers in pharmacology Vol. 15; p. 1375838 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
Frontiers
04.07.2024
Frontiers Media S.A |
| Subjects: | |
| ISSN: | 1663-9812, 1663-9812 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Introduction:
Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m
2
can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs).
Methods:
The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m
2
. The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m
2
; group 2 30–34.9 kg/m
2
; group 3 ≥35 kg/m
2
). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient’s kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates.
Results:
At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m
2
, the mean BSA was 1.98 m
2
, and 90% of patients had a BSA >1.73 m
2
. Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively −4% and −10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs.
Conclusion:
We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. |
|---|---|
| AbstractList | Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs).
Methods: The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m2. The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m2; group 2 30–34.9 kg/m2; group 3 ≥35 kg/m2). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient’s kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates.
Results: At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m2, the mean BSA was 1.98 m2, and 90% of patients had a BSA >1.73 m2. Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively −4% and −10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs.
Conclusion: We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m 2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs). Methods: The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m 2 . The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m 2 ; group 2 30–34.9 kg/m 2 ; group 3 ≥35 kg/m 2 ). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient’s kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates. Results: At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m 2 , the mean BSA was 1.98 m 2 , and 90% of patients had a BSA >1.73 m 2 . Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively −4% and −10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs. Conclusion: We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m 2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs). Methods: The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m 2 . The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m 2 ; group 2 30–34.9 kg/m 2 ; group 3 ≥35 kg/m 2 ). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient’s kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates. Results: At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m 2 , the mean BSA was 1.98 m 2 , and 90% of patients had a BSA >1.73 m 2 . Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively −4% and −10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs. Conclusion: We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs). The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m . The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m ; group 2 30-34.9 kg/m ; group 3 ≥35 kg/m ). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient's kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates. At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m , the mean BSA was 1.98 m , and 90% of patients had a BSA >1.73 m . Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively -4% and -10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs. We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs).Methods: The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m2. The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m2; group 2 30–34.9 kg/m2; group 3 ≥35 kg/m2). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient’s kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates.Results: At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m2, the mean BSA was 1.98 m2, and 90% of patients had a BSA >1.73 m2. Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively −4% and −10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs.Conclusion: We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs). Methods: The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m2. The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m2; group 2 30-34.9 kg/m2; group 3 ≥35 kg/m2). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient's kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates. Results: At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m2, the mean BSA was 1.98 m2, and 90% of patients had a BSA >1.73 m2. Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively -4% and -10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs. Conclusion: We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI.Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs). Methods: The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73 m2. The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m2; group 2 30-34.9 kg/m2; group 3 ≥35 kg/m2). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient's kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates. Results: At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m2, the mean BSA was 1.98 m2, and 90% of patients had a BSA >1.73 m2. Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively -4% and -10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs. Conclusion: We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. |
| Author | Pluquet, Maxime Liabeuf, Sophie Massy, Ziad A. Jacquelinet, Christian Laville, Solène M. Combe, Christian Frimat, Luc Laville, Maurice Metzger, Marie Fouque, Denis |
| AuthorAffiliation | 3 Centre for Research in Epidemiology and Population Health (CESP) , Paris-Saclay University , Versailles Saint Quentin University , Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche en Santé 1018 , Villejuif , France 9 Nephrology Department , Centre Hospitalier Régional Universitaire de Nancy , Vandoeuvre-lès-Nancy , France 8 CarMeN Institut National de la Santé et de la Recherche Médicale 1060 , et Association pour l'Utilisation du Rein Artificiel , Université de Lyon , Lyon , France 11 Department of Nephrology , Assistance Publique - Hôpitaux de Paris , Ambroise Paré University Hospital , Paris , France 2 MP3CV Laboratory , EA7517 , University of Picardie Jules Verne , Amiens , France 6 Institut National de la Santé et de la Recherche Médicale , U1026 , Université Bordeaux Segalen , Bordeaux , France 1 Division of Clinical Pharmacology , Amiens University Hospital , Amiens , France 5 Service de Néphrologie Transplantation Dialyse Aphérèse , Centre Hospitali |
| AuthorAffiliation_xml | – name: 4 Biomedecine Agency , Saint-Denis , France – name: 2 MP3CV Laboratory , EA7517 , University of Picardie Jules Verne , Amiens , France – name: 5 Service de Néphrologie Transplantation Dialyse Aphérèse , Centre Hospitalier Universitaire de Bordeaux , Bordeaux , France – name: 8 CarMeN Institut National de la Santé et de la Recherche Médicale 1060 , et Association pour l'Utilisation du Rein Artificiel , Université de Lyon , Lyon , France – name: 9 Nephrology Department , Centre Hospitalier Régional Universitaire de Nancy , Vandoeuvre-lès-Nancy , France – name: 1 Division of Clinical Pharmacology , Amiens University Hospital , Amiens , France – name: 3 Centre for Research in Epidemiology and Population Health (CESP) , Paris-Saclay University , Versailles Saint Quentin University , Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche en Santé 1018 , Villejuif , France – name: 7 Nephrology Department , Centre Hospitalier Lyon Sud , Université de Lyon , Pierre-Bénite , France – name: 10 Adaptation, Mesure et Evaluation en Santé - Approches Interdisciplinaires , Lorraine University , Vandoeuvre-lès-Nancy , France – name: 11 Department of Nephrology , Assistance Publique - Hôpitaux de Paris , Ambroise Paré University Hospital , Paris , France – name: 6 Institut National de la Santé et de la Recherche Médicale , U1026 , Université Bordeaux Segalen , Bordeaux , France |
| Author_xml | – sequence: 1 givenname: Maxime surname: Pluquet fullname: Pluquet, Maxime – sequence: 2 givenname: Marie surname: Metzger fullname: Metzger, Marie – sequence: 3 givenname: Christian surname: Jacquelinet fullname: Jacquelinet, Christian – sequence: 4 givenname: Christian surname: Combe fullname: Combe, Christian – sequence: 5 givenname: Denis surname: Fouque fullname: Fouque, Denis – sequence: 6 givenname: Maurice surname: Laville fullname: Laville, Maurice – sequence: 7 givenname: Luc surname: Frimat fullname: Frimat, Luc – sequence: 8 givenname: Ziad A. surname: Massy fullname: Massy, Ziad A. – sequence: 9 givenname: Sophie surname: Liabeuf fullname: Liabeuf, Sophie – sequence: 10 givenname: Solène M. surname: Laville fullname: Laville, Solène M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39027337$$D View this record in MEDLINE/PubMed https://u-picardie.hal.science/hal-04639466$$DView record in HAL |
| BookMark | eNp9Uk1zFCEQnbJimbjmD3iwOOphVwYYBk5WKn4kVVvlRc8UC80OcRZWYKK5-stlP0wlOcilqe73Ht3Ne9mchBigaV63eEGpkO_ddtBpQTBhi5b2naDiWXPWck7nUrTk5MH9tDnP-QbXQ6WknL1oTqnEpKe0P2v-fIS5DxZ-g0WQi9_oUm_rMW4gTaNOyPmxJF18DKgGyMjFhMoAyMbswxpFh2LSI9KheOv1Coo3yKZpnZEPaFuZEEpGv3wZkBlSDLX8w9sAd8j6DDrDq-a502OG82OcNd8_f_p2eTVffv1yfXmxnJsO0zIn0DsmQQuhGRiiJQA4YaSrs0jbcUkIo7ASGjswApuVph01QlgwTDIp6Ky5PujaqG_UNtVZ052K2qt9Iqa10ql2P4Lqe95T0mJGuGO66zRY4azVvOskrOoiZ82Hg9Z2Wm3AmjpjXcIj0ceV4Ae1jreqbUnXUdlVhXcHheEJ7-piqXY5zDiVjPPbtmLfHl9L8edUv0ltfDYwjjpAnLKiWBBOMWasQt88bOxe-d-PVwA5AEyKOSdw95AWq52z1N5ZaucsdXRWJYknJOPL3hR1OD_-j_oX7YbXHA |
| CitedBy_id | crossref_primary_10_1016_j_cbi_2025_111601 |
| Cites_doi | 10.1097/TP.0000000000004234 10.1053/j.ajkd.2023.01.453 10.1093/ckj/sfad039 10.1159/000180580 10.1093/ndt/gfv100 10.1111/bcp.12817 10.1111/bcp.13738 10.7326/0003-4819-130-6-199903160-00002 10.2337/dc13-S067 10.1111/ijcp.12960 10.1111/nep.13621 10.1016/j.jdiacomp.2016.01.016 10.1038/ki.2013.444 10.1186/s12882-020-01862-1 10.1093/ndt/gft388 10.47102/annals-acadmedsg.v38n12p1095 10.1001/archinte.1916.00080130010002 10.1111/sdi.12374 10.1056/NEJMoa2102953 10.2215/CJN.03940321 10.1016/S2214-109X(16)00071-1 10.1016/S0140-6736(23)01301-6 10.1016/j.kint.2022.06.013 10.7326/0003-4819-150-9-200905050-00006 10.1136/bmjopen-2017-020852 10.1016/j.nephro.2019.09.003 10.1093/ckj/sfz046 10.7326/M20-4366 10.1515/cclm-2022-0928 10.1038/kisup.2013.79 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Pluquet, Metzger, Jacquelinet, Combe, Fouque, Laville, Frimat, Massy, Liabeuf and Laville. Distributed under a Creative Commons Attribution 4.0 International License Copyright © 2024 Pluquet, Metzger, Jacquelinet, Combe, Fouque, Laville, Frimat, Massy, Liabeuf and Laville. 2024 Pluquet, Metzger, Jacquelinet, Combe, Fouque, Laville, Frimat, Massy, Liabeuf and Laville |
| Copyright_xml | – notice: Copyright © 2024 Pluquet, Metzger, Jacquelinet, Combe, Fouque, Laville, Frimat, Massy, Liabeuf and Laville. – notice: Distributed under a Creative Commons Attribution 4.0 International License – notice: Copyright © 2024 Pluquet, Metzger, Jacquelinet, Combe, Fouque, Laville, Frimat, Massy, Liabeuf and Laville. 2024 Pluquet, Metzger, Jacquelinet, Combe, Fouque, Laville, Frimat, Massy, Liabeuf and Laville |
| DBID | AAYXX CITATION NPM 7X8 1XC VOOES 5PM DOA |
| DOI | 10.3389/fphar.2024.1375838 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Pluquet et al |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_77673210426f4a55aed8fdda6559eb00 PMC11255395 oai:HAL:hal-04639466v1 39027337 10_3389_fphar_2024_1375838 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM ACXDI IAO IEA IHR IHW IPNFZ NPM RIG 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c503t-2e7f49ea88a4ec2a9eeef8c9f9029d5692243eb8a0fec80cba353c88dec494983 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001271814100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1663-9812 |
| IngestDate | Fri Oct 03 12:45:51 EDT 2025 Tue Sep 30 17:08:11 EDT 2025 Tue Oct 21 06:29:44 EDT 2025 Wed Oct 01 13:52:59 EDT 2025 Thu Jan 02 22:28:21 EST 2025 Tue Nov 18 22:42:26 EST 2025 Sat Nov 29 04:11:37 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | chronic kidney disease diabetes mellitus prescribing kidney function estimation oral antidiabetic drug pharmacoepidemiology |
| Language | English |
| License | Copyright © 2024 Pluquet, Metzger, Jacquelinet, Combe, Fouque, Laville, Frimat, Massy, Liabeuf and Laville. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c503t-2e7f49ea88a4ec2a9eeef8c9f9029d5692243eb8a0fec80cba353c88dec494983 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Nicolas Simon, Université de Lille, France These authors have contributed equally to this work Edited by: Giuseppe Remuzzi, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy Reviewed by: Carlos O. Mendivil, University of Los Andes, Colombia |
| ORCID | 0000-0002-0214-5567 0000-0001-5771-5996 0000-0001-5384-9006 0000-0003-4330-2925 0000-0002-9707-7199 |
| OpenAccessLink | https://doaj.org/article/77673210426f4a55aed8fdda6559eb00 |
| PMID | 39027337 |
| PQID | 3082630044 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_77673210426f4a55aed8fdda6559eb00 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11255395 hal_primary_oai_HAL_hal_04639466v1 proquest_miscellaneous_3082630044 pubmed_primary_39027337 crossref_primary_10_3389_fphar_2024_1375838 crossref_citationtrail_10_3389_fphar_2024_1375838 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-04 |
| PublicationDateYYYYMMDD | 2024-07-04 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2024 |
| Publisher | Frontiers Frontiers Media S.A |
| Publisher_xml | – name: Frontiers – name: Frontiers Media S.A |
| References | Girerd (B12) 2001; 30 Delanaye (B7); 16 Tesfaye (B32) 2017; 71 Hassan (B15) 2009; 38 Muller (B24) 2016; 30 Weir (B35) 2023 Laville (B19) 2018; 84 Vlasschaert (B34) 2020; 25 Kazancioğlu (B17) 2013; 3 Ong (B26) 2023; 402 Cockcroft (B6) 1976; 16 (B2) 2013; 36 Berdougo (B3) 2020; 16 Schmidt (B30) 2019; 12 Ene-Iordache (B11) 2016; 4 B13 Castelino (B5) 2020; 21 (B14) 2015; 30 Pottel (B27) 2021; 174 Kimura (B18) 2021; 16 Nolin (B25) 2015; 28 Varghese (B33) 2023 (B36) 2015 Inker (B16) 2021; 385 Levey (B21) 2009; 150 (B28) 2022 Levin (B22) 2014; 85 Bouquegneau (B4) 2016; 81 Stengel (B31) 2014; 29 Delanaye (B8) 2022; 106 Delanaye (B9); 61 Du Bois (B10) 1916 Rossing (B29) 2022; 102 Lyu (B23) 2023; 82 Alwhaibi (B1) 2018; 8 Levey (B20) 1999; 130 |
| References_xml | – volume: 106 start-page: 2443 year: 2022 ident: B8 article-title: The new 2021 CKD-EPI equation without race in a European cohort of renal transplanted patients publication-title: Transplantation doi: 10.1097/TP.0000000000004234 – volume: 82 start-page: 505 year: 2023 ident: B23 article-title: Discordance in GFR estimating equations and dosing guidance by body mass index and age publication-title: Am. J. Kidney Dis. doi: 10.1053/j.ajkd.2023.01.453 – volume: 16 start-page: 1375 ident: B7 article-title: New and old GFR equations: a European perspective publication-title: Clin. Kidney J. doi: 10.1093/ckj/sfad039 – volume: 16 start-page: 31 year: 1976 ident: B6 article-title: Prediction of creatinine clearance from serum creatinine publication-title: Nephron. doi: 10.1159/000180580 – volume: 30 start-page: ii1 year: 2015 ident: B14 article-title: Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) publication-title: Nephrol. Dial. Transpl. doi: 10.1093/ndt/gfv100 – volume-title: StatPearls year: 2023 ident: B33 article-title: Polypharmacy – volume: 81 start-page: 349 year: 2016 ident: B4 article-title: Creatinine-based equations for the adjustment of drug dosage in an obese population publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/bcp.12817 – volume: 84 start-page: 2811 year: 2018 ident: B19 article-title: Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/bcp.13738 – volume: 130 start-page: 461 year: 1999 ident: B20 article-title: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group publication-title: Ann. Intern Med. doi: 10.7326/0003-4819-130-6-199903160-00002 – volume: 36 start-page: S67 year: 2013 ident: B2 article-title: Diagnosis and classification of diabetes mellitus publication-title: Diabetes Care doi: 10.2337/dc13-S067 – volume: 71 start-page: e12960 year: 2017 ident: B32 article-title: Inappropriate prescribing in chronic kidney disease: a systematic review of prevalence, associated clinical outcomes and impact of interventions publication-title: Int. J. Clin. Pract. doi: 10.1111/ijcp.12960 – volume: 25 start-page: 29 year: 2020 ident: B34 article-title: De-indexed estimated glomerular filtration rates: a simple step towards improving accuracy of drug dosing of renally excreted medications in moderate to severe obesity publication-title: Nephrol. Carlt. doi: 10.1111/nep.13621 – volume: 30 start-page: 675 year: 2016 ident: B24 article-title: Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations? publication-title: J. Diabetes Complicat. doi: 10.1016/j.jdiacomp.2016.01.016 – volume-title: R: a language and environment for statistical computing year: 2022 ident: B28 – volume: 85 start-page: 49 year: 2014 ident: B22 article-title: Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward publication-title: Kidney Int. doi: 10.1038/ki.2013.444 – volume: 21 start-page: 216 year: 2020 ident: B5 article-title: Quality use of medicines in patients with chronic kidney disease publication-title: BMC Nephrol. doi: 10.1186/s12882-020-01862-1 – volume: 29 start-page: 1500 year: 2014 ident: B31 article-title: The French chronic kidney disease-renal Epidemiology and information network (CKD-REIN) cohort study publication-title: Nephrol. Dial. Transpl. doi: 10.1093/ndt/gft388 – volume: 38 start-page: 1095 year: 2009 ident: B15 article-title: Drug use and dosing in chronic kidney disease publication-title: Ann. Acad. Med. Singap doi: 10.47102/annals-acadmedsg.v38n12p1095 – start-page: 863 year: 1916 ident: B10 article-title: Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known publication-title: Archives Intern. Med. doi: 10.1001/archinte.1916.00080130010002 – ident: B13 – volume: 28 start-page: 325 year: 2015 ident: B25 article-title: A synopsis of clinical pharmacokinetic alterations in advanced CKD publication-title: Semin. Dial. doi: 10.1111/sdi.12374 – volume: 385 start-page: 1737 year: 2021 ident: B16 article-title: New creatinine- and cystatin C–based equations to estimate GFR without race publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2102953 – volume: 16 start-page: 1797 year: 2021 ident: B18 article-title: Association of polypharmacy with kidney disease progression in adults with CKD publication-title: Clin. J. Am. Soc. Nephrol. doi: 10.2215/CJN.03940321 – volume: 30 start-page: 1044 year: 2001 ident: B12 article-title: Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic publication-title: Presse Med. – volume: 4 start-page: e307 year: 2016 ident: B11 article-title: Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study publication-title: Lancet Glob. Health doi: 10.1016/S2214-109X(16)00071-1 – volume: 402 start-page: 203 year: 2023 ident: B26 article-title: Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 publication-title: Lancet doi: 10.1016/S0140-6736(23)01301-6 – volume: 102 start-page: 990 year: 2022 ident: B29 article-title: Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence publication-title: Kidney Int. doi: 10.1016/j.kint.2022.06.013 – volume: 150 start-page: 604 year: 2009 ident: B21 article-title: A new equation to estimate glomerular filtration rate publication-title: Ann. Intern Med. doi: 10.7326/0003-4819-150-9-200905050-00006 – volume: 8 start-page: e020852 year: 2018 ident: B1 article-title: Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia publication-title: BMJ Open doi: 10.1136/bmjopen-2017-020852 – volume: 16 start-page: 59 year: 2020 ident: B3 article-title: Clarification de la méthode utilisée pour adapter la posologie des médicaments chez les patients insuffisants rénaux: étude CLEAR publication-title: Néphrologie Thérapeutique doi: 10.1016/j.nephro.2019.09.003 – volume-title: StatPearls year: 2023 ident: B35 article-title: BMI classification percentile and cut off points – volume: 12 start-page: 663 year: 2019 ident: B30 article-title: Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study publication-title: Clin. Kidney J. doi: 10.1093/ckj/sfz046 – volume-title: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function year: 2015 ident: B36 – volume: 174 start-page: 183 year: 2021 ident: B27 article-title: Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate: a cross-sectional analysis of pooled data publication-title: Ann. Intern Med. doi: 10.7326/M20-4366 – volume: 61 start-page: 44 ident: B9 article-title: The new, race-free, Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation to estimate glomerular filtration rate: is it applicable in Europe? A position statement by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) publication-title: Clin. Chem. Laboratory Med. (CCLM) doi: 10.1515/cclm-2022-0928 – volume: 3 start-page: 368 year: 2013 ident: B17 article-title: Risk factors for chronic kidney disease: an update publication-title: Kidney Int. Suppl. doi: 10.1038/kisup.2013.79 |
| SSID | ssj0000399364 |
| Score | 2.3589697 |
| Snippet | Introduction:
Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of... Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m can pose... Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of... |
| SourceID | doaj pubmedcentral hal proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1375838 |
| SubjectTerms | chronic kidney disease diabetes mellitus Human health and pathology kidney function estimation Life Sciences oral antidiabetic drug pharmacoepidemiology Pharmacology prescribing Urology and Nephrology |
| Title | De-indexed estimated glomerular filtration rates for the dosing of oral antidiabetic drugs in patients with chronic kidney disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39027337 https://www.proquest.com/docview/3082630044 https://u-picardie.hal.science/hal-04639466 https://pubmed.ncbi.nlm.nih.gov/PMC11255395 https://doaj.org/article/77673210426f4a55aed8fdda6559eb00 |
| Volume | 15 |
| WOSCitedRecordID | wos001271814100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ3Pb9MwFMctmDhwQfwm_JgeCO3CwpLYSezjgE07jKmHIfUWOfbzGq0kU9NO6oUDfzl-SdY1IMGFS1SlTtLmveR9bb_3MWPvjdQCS4chilyFwkQ6VN7sYaZVLJ1UmY27QuHT_OxMTqdqsrXUF-WE9Xjg_sYdEG2G6kx8JHFCp6lGK521OvNSmNa9obdvlKutzlT3Dqa4m4m-Ssb3wtSBu5pp4n8m4mPMc5osHEWiDtjv48uM0iH_1Jq_p0xuxaDjh-zBIB7hsP_Rj9gdrB-zvUlPn17vw_ltMVW7D3swueVSr5-wn18w7OCIaIHYGl6r-k8X8-Y7LigZFVw1HyC6QACJFrygBS8QwTY0ogCNA6rnB2-Mqh-zrQzYxeqihaqGgdDaAg3tgumhu3BZ2RrXMMwDPWXfjo_OP5-EwxIMoUkjvgwTzJ1QqCWZ1CRaIaKTRjkVJcqmmfIKgGMpdeTQyMiUmqfcSGnREPZG8mdsp25qfMEgM0oYUZZG80igRmW99su9_IpchnmSBSy-MUdhBj45LZMxL3w_hUxYdCYsyITFYMKAfdgcc9XTOf7a-hNZedOSyNrdDu9vxeBvxb_8LWDvvI-MznFyeFrQPoKvEa7_Og7Y2xsXKvzjSnMwusZm1RZEB-ooZyJgz3uX2pyLK4IL8TxgcuRso4uNv6mrWYcE96o5TblKX_6Pv_iK3afb1iUli9dsZ7lY4Rt2z1wvq3axy-7mU7nbPW5--_XH0S_oyDMi |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=De-indexed+estimated+glomerular+filtration+rates+for+the+dosing+of+oral+antidiabetic+drugs+in+patients+with+chronic+kidney+disease&rft.jtitle=Frontiers+in+pharmacology&rft.au=Maxime+Pluquet&rft.au=Maxime+Pluquet&rft.au=Marie+Metzger&rft.au=Christian+Jacquelinet&rft.date=2024-07-04&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=15&rft_id=info:doi/10.3389%2Ffphar.2024.1375838&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_77673210426f4a55aed8fdda6559eb00 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |